You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Muscular Dystrophy Ireland disappointed with NCPE decision

By Dermot - 04th May 2016 | 5 views

“It is only fair and reasonable to expect Irish children to have the same opportunities as the children in other european countries who have access to this medication,” said Mr John Bennett of MDI.

“It is our information that this new treatment would only apply in Ireland to a very small number of patients in the low single digits.”

Translarna is a new treatment for people with a particular type of Duchenne Muscular Dystrophy. MDI has raised access to this therapy on a number of occasions in recent months, including on World Duchenne Awareness Day, and in various meetings with public representatives and other stakeholders.

“However, for those young people it would make a huge difference in slowing progression of the condition and in keeping them on their feet for longer,” said Mr John Bennett of MDI.

“It means that they may experience more of what life has to offer and delay the requirement for other medical and social care supports. For young people and their families whose quality of life and life expectancy is significantly impacted by this condition, this is of immense value.”

MDI noted that while this recommendation has been made by the NCPE, the final decision on reimbursement rests with the HSE.

“We are now calling on the HSE to enter into discussions with the manufacturer and to come to an arrangement which would make the therapy available here and to do so in as timely a manner as possible,” MDI Ireland said in their statement today.


Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]